Strategia Therapeutics Spins Out SOLA Biosciences to Commercialize Tapboost® Technology

Posted on February 23, 2016February 22, 2016 by Editor

Strategia Therapeutics Spins Out SOLA Biosciences to Commercialize Tapboost® Technology

BOSTON–(BUSINESS WIRE) – Strategia Therapeutics Inc. (Strategia) announced its first spinout company, SOLA Biosciences LLC (SOLA). Headquartered in Boston, SOLA focuses on Tapboost® technology and globally collaborates with various pharmaceutical companies and researchers.

Strategia is an innovative pharmaceutical R&D company that provides strategy, management, and optimization of global drug development programs with a new model for collaborative drug development by bringing together small, specific global expert teams for each drug project. Strategia has developed its proprietary technology, Tapboost®, to control protein folding and the protein production process. This breakthrough platform significantly improves targeted protein production such as antibodies and Fc-fusion proteins.

“We have discovered the amino acid chaperone motifs that enhance protein production only for targeted proteins or antibodies of interest,“ says Dr. Akinori Hishiya, Principal Scientist of SOLA. “Our data shows enhanced expression more than 10-20 times for various “difficult-to-express” proteins such as FVIII-Fc.”

SOLA has established ten MTAs (material transfer agreements) so far with pharmaceutical and biotech companies including major ones to evaluate the Tapboost® technology for their therapeutic biologics and new target molecules.

“One of the reasons we have spun out the SOLA from Strategia is that while SOLA focuses on the application of the Tapboost® technology, Strategia will be able to focus more on its mission which is to swiftly create needed drugs for the patients at lower cost,” says Dr. Keizo Koya, President and CEO of Strategia. “The other primary reason is that Tapboost® technology could accelerate the R&D process of other companies and research, not just for Strategia. Our technology will also decrease the cost of biologics since it can express protein more productively than before. There is an expected wide application range of Tapboost® technology, which will contribute to science, researchers, R&D companies, and most importantly, people who benefit from their hard work.”

About Strategia Therapeutics, Inc. (Strategia)
Strategia is an integrated pharmaceutical company with the goal of delivering new therapeutics faster, more efficiently, and at lower overall cost to the drug development process than existing R&D big pharma models. Strategia organizes small, dedicated teams of global experts specific for each new therapeutic project to guide strategy, quality, research & development, and commercialization. This approach streamlines existing R&D and allows us to bring exciting new investigational therapeutics to patients more rapidly and efficiently.

Contact:
Strategia Therapeutics, Inc.
+1-781-761-0123 (office)
Contact@StrategiaTx.com (email)
http://www.StrategiaTx.com (website)

SOLA BioSciences, LLC.
Contact@Sola-bio.com (email)
http://sola-bio.com (Website)

Strategia Therapeutics Initiates a Phase 1 Clinical Trial of the Anti-cancer Agent “FF-10502″ For FUJIFILM in Patients with Advanced Cancers

Posted on February 19, 2016February 19, 2016 by Editor

Strategia Therapeutics Initiates a Phase 1 Clinical Trial of the Anti-cancer Agent “FF-10502″ For FUJIFILM in Patients with Advanced Cancers

BOSTON–(BUSINESS WIRE) – Strategia Therapeutics (Strategia), a primary global strategic drug development provider for FUJIFILM Pharmaceuticals U.S.A., Inc. (FPHU), has initiated a Phase 1 clinical trial of FUJIFILM’s anti-cancer agent FF-10502 in the United States in patients with advanced solid tumor cancers and lymphoma. The trial is being performed under the direction of Drs. Filip Janku, M.D. and Gerald Falchook, M.D. as Co-Principal Investigators. Dr. Janku is Assistant Professor in the Department of Investigational Therapeutics at MD Anderson Cancer Center, Houston, TX, and Dr. Falchook is Director, Drug Development Program, Sarah Cannon Research Institute, Denver, CO. Both Drs. Janku and Falchook are experts in early phase cancer clinical research studies of novel new agents.
FF-10502 is an antimetabolite anti-cancer drug that inhibits DNA synthesis. It has demonstrated preclinical activity against tumors resistant to gemcitabine therapy, a common anti-cancer agent used in the treatment of lymphoma and advanced ovarian, metastatic breast, locally advanced and metastatic lung and pancreatic cancers.
“We are very excited to be collaborating with FPHU and Strategia on this important clinical trial in patients with advanced solid tumors and lymphomas,” said Gerald Falchook, M.D. “This drug may provide another alternative for patients who have failed conventional chemotherapeutic approaches, and we are pleased to be furthering this research at our institution.”
“Strategia is pleased to initiate this important clinical trial for FPHU with these two esteemed investigators at such prestigious institutions”, said Thomas J. Myers, MD, Strategia Chief Medical Officer. “FF-10502 has shown activity against important gemcitabine-resistant cancers, and we are now poised to bring this investigational new drug to patients in the clinical setting.”

Contact:
Strategia Therapeutics, Inc.
+1-781-761-0123 (office)
Contact@StrategiaTx.com (email)
http://www.StrategiaTx.com (website)

Strategia Therapeutics Initiates a Phase 1 Clinical Trial of the Radioimmunotherapeutic “FF-21101″ For FUJIFILM in Patients with Advanced Cancers

Posted on January 15, 2016January 15, 2016 by Editor

Strategia Therapeutics Initiates a Phase 1 Clinical Trial of the Radioimmunotherapeutic “FF-21101″ For FUJIFILM in Patients with Advanced Cancers

P-cadherin is a protein that is over-expressed in many common types of cancer, including lung, pancreatic and colon cancers, and is implicated in tumor growth and cancer disease progression. FF-21101(90Y) is a combination agent containing a monoclonal antibody against P-cadherin radiolabeled with Yttrium-90 (90Y). FF-21101(90Y) inhibits the growth of P-cadherin-expressing solid tumor cancers and, conjugated with the radionuclide, is expected to be more effective than an antibody therapy targeted to P-cadherin alone.

MD Anderson is one of the world’s top general cancer centers with over 10,000 patients enrolled in therapeutic clinical trials each year and approximately 20,000 employees. Strategia is able to utilize one of the world’s top-level clinical testing facilities at MD Anderson under a Strategic Alliance Agreement to carry out the Phase 1 clinical trial to gain safety and preliminary proof of activity in cancer patients at an early stage.

“Radioimmunotherapeutic antibody drug conjugates are a relatively new approach for clinical investigational research, with the success of drugs targeting CD20, like Zevalin®, Bexxar® and the newer investigational agents that target solid tumor cell surface markers conjugated to a radionuclide. Coupling a radionuclide with targeted drug therapy is expected to be more effective than either modality alone and an important next step for newer targeted antibody-radionuclide conjugate therapeutics for the treatment of advanced solid tumors“, said Dr. Linda Paradiso, Chief Operating Officer for Strategia.

About Strategia Therapeutics, Inc. (Strategia)
Strategia is an integrated pharmaceutical company with the goal of delivering new therapeutics faster, more efficiently, and at lower overall cost to the drug development process than existing R&D big pharma models. Strategia organizes small, dedicated teams of global experts specific for each new therapeutic project to guide strategy, quality, research & development and commercialization. This approach streamlines existing R&D and allows us to bring exciting new investigational therapeutics to patients more rapidly and efficiently.

Contact:
Strategia Therapeutics, Inc.
+1-781-761-0123 (office)
Contact@StrategiaTx.com (email)
http://www.StrategiaTx.com (website)

Strategia Therapeutics Announces Progress in a Phase 1 Clinical Trial of the Anti-cancer Agent “FF-10501-01” for FUJIFILM in Patients with Advanced Hematologic Malignancies

Posted on December 24, 2015December 24, 2015 by Editor

Strategia Therapeutics Announces Progress in a Phase 1 Clinical Trial of the Anti-cancer Agent “FF-10501-01” for FUJIFILM in Patients with Advanced Hematologic Malignancies

BOSTON–(BUSINESS WIRE) – Strategia Therapeutics, Inc. (Strategia), is announcing progress in a Phase 1 clinical trial of FUJIFILM’s anti-cancer agent, FF-10501-01 in the United States in patients with relapsed or refractory myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The emerging results reveal that, in the Phase 1 dose escalation phase thus far (5 dose cohorts), FF-10501-01 has been highly tolerable and has demonstrated promising preliminary efficacy.

These results were published at the 57th American Society of Hematology Meeting by Professor Guillermo Garcia-Manero MD, Principal Investigator, University of Texas MD Anderson Cancer Center.

Strategia is a primary global strategic drug development provider for FUJIFILM Pharmaceuticals U.S.A., Inc. (FPHU) facilitated the preclinical study in hypo-methylating agent (HMA) resistant leukemia cell lines as well as the design and execution of the Phase 1 clinical trial of FF-10501-01 in patients with hematologic malignancies in the United States both conducted at MD Anderson Cancer Center.

In the preclinical study, FF-10501-01 produced potent anti-proliferative and pro-apoptotic effects in AML cell lines through inhibition of de novo guanine nucleotide synthesis, with similar positive effects in HMA-resistant AML cell lines.

In the Phase 1 study, a total of 5 dose cohorts have been enrolled (50 – 400 mg/m2 orally twice daily) in 17 patients (13 AML, 4 MDS). Although the trial is still underway, preliminary findings thus far are:
• FF-10501-01 has been well-tolerated to date
• FF-10501-01 produced 2 PRs lasting 2 cycles among 13 patients with relapsed/refractory AML, and 4 patients remain on treatment after 5 -15 cycles
• FF-10501-01 produced 1 bone marrow CR among 4 patients with relapsed/refractory MDS
• PK parameters for FF-10501-01 were linear across the dose range tested
• PD analysis showed potent xanthosine monophosphate suppression in patients receiving ≥ 50 mg/m2 BID

Additional Phase 1 dose cohorts of 500, 600 and 800 mg/m2 BID will be assessed. The Phase 2 portion of the study will open when a recommended Phase 2 dose is determined.

“We are deeply committed to giving our new pharmaceutical R&D platform for FPHU which looks for an innovative and efficient way of globally developing their unique oncology pipelines such as FF-10501-01.” says Dr. Keizo Koya, CEO of Strategia. “Our special alliance and innovative collaboration with MD Anderson and Fujifilm will translate the highest-quality science into proven clinical success in an efficient and nimble manner for patients in needs.”

About Strategia Therapeutics, Inc. (Strategia)
Strategia is an innovative pharmaceutical R&D company with experience in developing, managing and optimizing global drug development programs. Its mission is to create a new model for collaborative drug development by bringing together small, global expert teams, each of which has expertise specific to a single drug. By focusing its efforts in this way, Strategia rapidly and successfully moves each project forward to completion while keeping internal infrastructure small and streamlined.

Contact:
Strategia Therapeutics, Inc.
+1-781-761-0123 (office)
Contact@StrategiaTx.com (email)
http://www.StrategiaTx.com (website)

New Website Launch

Posted on August 10, 2015August 11, 2015 by Editor

Strategia Therapeutics Announces New Website Launch

BOSTON–(BUSINESS WIRE) – Strategia Therapeutics Inc. (Strategia) today announced the launch of a new, redesigned version of its website, www.strategiatx.com. The new Startegia site offers a clearer and more attractive design, easy-to-navigate functionality, and a content-rich site experience with various updated information such as its mission, patient-centric approach, global team approach, team members and capabilities of Strategia, Medical Advisory Board (MAB), featured program, and Tapboost® technology written in both English and Japanese.

“We are excited about our new website launch and the robust information it provides for clients, investors, partners, and media to better understand Strategia, says President and CEO Keizo Koya, Ph.D. “The new website and brand refresh are more closely aligned with the company’s strategic vision for growth and expansion over the next decade, and beyond. Strategia’s vision is to change the existing drug research and development paradigm. By creating a nimble approach to drug development, the pharmaceutical R&D team produced by Stratrgia can reduce overall costs and time to market, thereby making new, affordable drugs available to patients whose medical needs would otherwise be unmet.”

“It is a great pleasure to collaborate with Strategia to create a new designed Website.” says Diane Fassino, President of Fassino/Design. “The team members and their innovative approach to dramatically improving current pharmaceutical R&D for patients are amazingly inspiring. The new website hopefully helps excellent people in the world to share their values and partner with Strategia’s team to develop new effective drugs for patients in need. Strategia’s new logo is a direct representation of their team approach as well as their vision of a brighter future.”

Strategia’s approach is a dramatic break from existing R&D models. Instead of using one vertical organization to create many different drugs, Strategia pulls together customized global project teams for each new therapeutic agent under development. These teams, which Strategia manages, are made up of partners with specific expertise relevant to a certain drug or medical condition.

“We place drug development strategy first,” says Koya. “This approach streamlines existing research and development extensively, and it lets Strategia create new, effective therapeutics faster and more efficiently than ever before,” he adds. “Our primary goal is positively impacting patient health—so our success is measured by how quickly and effectively we make new drugs accessible to those patients,” he says.

The new www.strategiatx.com allows for more potential partners and clients to easily understand innovative approach of the new global pharmaceutical R&D to successfully and efficiently develop new pharmaceutical drugs for patients in need.

Contact:
Strategia Therapeutics, Inc.
+1-781-761-0123 (office)
Contact@StrategiaTx.com (email)
http://www.StrategiaTx.com (website)

Oncology/Hematology Medical Advisory Board

Posted on July 20, 2015July 21, 2015 by Editor

Strategia Therapeutics Forms Oncology/Hematology Medical Advisory Board

BOSTON–(BUSINESS WIRE) – Strategia Therapeutics, Inc. (Strategia) is an innovative pharmaceutical R&D company that provides strategy, management and optimization of global drug development programs with a new model for collaborative drug development by bringing together small, specific global expert teams for each drug project. Strategia announced today the formation of its first oncology/hematology Medical Advisory Board (MAB) to provide strategic medical/scientific advice and counsel to the Strategia board of directors and senior management team. The oncology/hematology MAB is comprised of three recognized oncology/hematology experts from leading academic facilities and research institutions. All three individuals have devoted their time and medical expertise to improving the lives of people afflicted with cancer and hematologic malignancies.
The three member board, chaired by Dr. Daniel D. Von Hoff, includes:

Daniel D. Von Hoff, MD, FACP, Physician in Chief, Distinguished Professor at TGen (Translational Genomics Research Institute) in Phoenix, Arizona, Chief Scientific Officer for US Oncology Research and for Honor Health’s Clinical Research Institute, Professor of Medicine, Mayo Clinic, Scottsdale, AZ. He and his colleagues were involved in the initial development of mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, nab-paclitaxel, vismodegib and others. Dr. Von Hoff is an internationally recognized expert in pancreatic cancer. Dr. Von Hoff has published more than 620 papers, 137 book chapters and over 1050 abstracts. He received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care. Dr. Von Hoff is the past President of the American Association for Cancer Research (the world’s largest cancer research organization).

Alan F. List, MD, President and Chief Executive Officer of Moffitt Cancer Center in Tampa, FL. Dr. List is internationally recognized as an expert in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). His pioneering work led to the development of lenalidomide (Revlimid®) from the laboratory to clinical approval. Dr. List previously served as Executive Vice President and Physician-in-Chief, Vice Deputy Physician-in-Chief, and Chief of the Malignant Hematology Division at Moffitt, where he holds the Morsani Endowed Chair. He is the author of more than 300 peer-reviewed articles and the Clinician’s Manual on Myelodysplastic Syndromes (2008).

Alex A. Adjei, MD, PhD, FACP, Professor of Oncology and Chair of the Department of Medicine as well as Senior Vice-President for Clinical Research at the Roswell Park Cancer Institute (RPCI) in Buffalo, NY, the Katherine Anne Gioia Chair in Cancer Medicine at RPCI, Professor of Medicine and an Academic Scholar in Medicine at the State University of New York in Buffalo. Dr Adjei has served as chair or vice-chair in a number of US National Cancer Institute committees. He is currently the co-chair of the Thoracic Malignancies Steering Committee. He is the Editor-in-Chief of the Journal of Thoracic Oncology and a member of the Board of Directors of the International Association for the Study of Lung Cancer (IASLC). He has a long track record in experimental therapeutics and early phase oncology drug development. He received the first ASCO Drug Development Research Professorship in 2012. He has authored 227 publications dealing primarily with preclinical pharmacology, phase I trials and novel therapeutics/phase II trials of lung cancer.

“I am glad to see the Strategia team pursuing some agents which have already demonstrated anticancer activity in their initial Phase 1 trials. Those leads need to be followed”, said Dr. Daniel D. Von Hoff, MAB Chair.

“Strategia Therapeutics’ patient-focused approach to new therapy development is extraordinary and is complimented by a breadth of exciting agents in their pipeline,” Dr. Alan F. List stated.

“It is a distinct pleasure to be a member of the Strategia oncology/hematology MAB,” Dr. Alex A. Adjei stated; “Strategia’s new drug development approach and vision is truly refreshing, as it places patient benefit as the primary focus of all decision-making. I am honored to contribute to what Strategia is trying to do for patients.”

“The medical/scientific advice and guidance provided by these 3 experts will assist Strategia in properly selecting and executing the development of novel agents for patients. In addition, it will further support the mission of Strategia Therapeutics: to help patients in need by accelerating the research and development of high quality, clinically viable drugs for truly unmet needs.” says Thomas Myers, MD, FACP, Chief Medical Officer of Strategia.

Together, Strategia and the Medical Advisory Board believe that they can change the future of the pharmaceutical industry with a new model for effective drug research and development for patients and their providers.

About Strategia Therapeutics, Inc. (Strategia)

Strategia is an innovative pharmaceutical R&D company with experience in developing, managing and optimizing global drug development programs. Its mission is to create a new model for collaborative drug development by bringing together small, global expert teams, each of which has expertise specific to a single drug. By focusing its efforts in this way, Strategia rapidly and successfully moves each project forward to completion while keeping internal infrastructure small and streamlined.

Contact:
Strategia Therapeutics, Inc.
+1-781-761-0123 (office)
Contact@StrategiaTx.com (email)
http://www.StrategiaTx.com (website)

Phase 1/2a Clinical Trial of E6201

Posted on April 22, 2015June 11, 2015 by Editor

Strategia Therapeutics Initiates a Phase 1/2a Clinical Trial of the Anti-cancer Agent E6201 in Patients with Advanced Hematologic Malignancies

BOSTON–(BUSINESS WIRE) – Strategia Therapeutics, Inc. (Strategia) – from the company’s former name, Boston Strategics. Corp. – has begun a Phase 1/2a clinical trial of anti-cancer agent E6201 in patients with advanced hematologic malignancies, including relapsed or refractory acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). The trial is being carried out at the University of Texas M.D. Anderson Cancer Center with Gautam Borthakur, M.D., as the Principal Investigator.

There are approximately 19,000 new cases of AML in the U.S. each year, with over 10,000 deaths; the number of patients estimated to be living with AML is 40,000. Patients relapsed or refractory to currently available therapy have limited options. MDS is a type of hematological malignancy, in which the disorder of blood-forming “hematopoietic stem cells” causes inefficient production of blood cells triggering cytopenia. It is also a refractory disease for some patients with poor prognosis, progressing to acute myeloid leukemia. The U.S. incidence of MDS is 14,000 cases per year, most of them in the senior age group.

E6201, discovered by Eisai Co., Ltd., is a dual-inhibitor of FMS-like tyrosine kinase 3 (FLT-3) and mitogen-activated protein (enzyme) kinase (MEK). Activation of FLT3 is observed in patients with AML carrying either internal tandem duplication (ITD) or point (D835) mutations in the FLT3 gene, and E6201 has demonstrated activity against both mutations. The Ras/Raf signaling pathway signals through the downstream signal transducers MEK1 and extracellular signal-related kinases (ERK) and activation of this pathway is seen in AML cells of patients failing FLT3 inhibitor therapy. Preclinical studies conducted by Dr. Borthakur indicate inhibition of both pathways is important to durable responses.

The University of Texas MD Anderson Cancer Center is one of the world’s top general cancer centers with over 10,000 patients enrolled in therapeutic clinical trials each year and approximately 20,000 employees. Strategia is able to utilize the world’s top-level clinical testing functions available at the MD Anderson Cancer Center under a Strategic Alliance Agreement to carry out Phase 1 and early Phase 2 clinical trials to gain safety and preliminary proof of activity in cancer patients at an early stage. “This drug may be important for patients with advanced hematologic malignancies who have failed conventional therapeutics, including single-agent FLT3 inhibitors”, said Gautam Borthakur, M.B.B.S., Associate Professor of Leukemia at M.D. Anderson Cancer Center. By inhibition of both the FLT3 and MEK pathways we hope to provide more durable clinical benefit than through inhibition of one pathway alone. This study will build on our preclinical evidence, and further this important clinical research at our institution.”

“This is the first proprietary drug under full development by Strategia. Both FLT3 and MEK are important new targets for the treatment of advanced hematologic malignancies. Inhibition of both pathways known to be involved in the progression of FLT3 positive AML is an important next step in new targeted therapeutics for the treatment of this disease“, said Dr. Linda Paradiso, Head of Drug Development for Strategia. “We have in-licensed E6201 from Eisai Co., Ltd. and they have been an excellent collaborative partner. Both companies are fully committed to deliver breakthrough therapies using innovative approaches to achieve industry benchmark-beating timelines, quality, and financial investments for important novel anti-cancer agents”.

About Strategia Therapeutics, Inc. (Strategia)

Strategia is an innovative pharmaceutical R&D company with experience in developing, managing and optimizing global drug development programs. Its mission is to create a new model for collaborative drug development by bringing together small, global expert teams, each of which has expertise specific to a single drug. By focusing its efforts in this way, Strategia rapidly and successfully moves each project forward to completion while keeping internal infrastructure small and streamlined.

Contact:
Strategia Therapeutics, Inc.
+1-781-761-0123 (office)
Contact@StrategiaTx.com (email)
http://www.StrategiaTx.com (website)

Company Name Change

Posted on April 8, 2015June 11, 2015 by Editor

Boston Strategic Corporation Announces Name To Strategia Therapeutics, Inc.

BOSTON–(BUSINESS WIRE) – Boston Strategic Corporation, an innovative pharmaceutical R&D company that specializes in streamlining the drug development processes, today announced its new name: Strategia Therapeutics, Inc., effective immediately.

The change, which comes on the Boston-based company’s third anniversary, more accurately reflects its emphasis on serving patients in need, says President and CEO Keizo Koya, Ph.D. “Strategia’s vision is to change the existing drug research and development paradigm,” Koya says. By creating a nimble approach to drug development, he notes, the company can reduce overall costs and time to market, thereby making new, affordable drugs available to patients whose medical needs would otherwise be unmet.

Strategia’s approach is a dramatic break from existing R&D models, which rely mainly on a single company’s in-house research, testing, and production. Instead of using one team to create many different drugs, Strategia pulls together customized global project teams for each new therapeutic agent under development. These teams, which Strategia manages, are made up of partners with specific expertise relevant to a certain drug or medical condition.

Strategia was founded in April 2012. Since then, the company has collaborated with global partners who have the same vision and passion for improved patient care, and has advanced many new pharmaceutical R&D projects from research to clinical development. Its core team of strategists collectively have more than 200 years of experience in drug development.

The company’s new logo design and tagline (”A New Vision. A Better Future for Patients,”) symbolize its new mission.

Former name：Boston Strategics Corp.
New name：Strategia Therapeutics, Inc.

【Startegia Therapeutics, Inc. Profile】
Company Name: Strategia Therapeutics, Inc.
President and CEO: Keizo Koya, Ph.D.
Headquarter Address: 214 Union Wharf, Boston, MA 02109-1204, USA
About Strategia Therapeutics, Inc. (Strategia)

Strategia is an innovative pharmaceutical R&D company with experience in developing, managing and optimizing global drug development programs. Its mission is to create a new model for collaborative drug development by bringing together small, global expert teams, each of which has expertise specific to a single drug. By focusing its efforts in this way, Strategia rapidly and successfully moves each project forward to completion while keeping internal infrastructure small and streamlined.

Contact:
Strategia Therapeutics, Inc.
+1-781-761-0123 (office)
Contact@StrategiaTx.com (email)
http://www.StrategiaTx.com (website)

Risk-Sharing Agreement with MDACC

Posted on December 16, 2014June 11, 2015 by Editor

Boston Strategics Enters into an Innovative Risk-Sharing Agreement with the MD Anderson Cancer Center to Conduct a Phase 1/2a Clinical Trial of E6201 in Patients with Advanced Hematologic Malignancies Including Acute Myeloid Leukemia

BOSTON–(BUSINESS WIRE)–Boston Strategics Corporation (BSC), an integrated clinical-stage drug research and development (R&D) company, Boston, MA, today announced that it has entered into a risk-sharing agreement with the University of Texas MD Anderson Cancer Center (MD Anderson) to conduct a Phase 1/2a clinical trial of E6201 in patients with advanced hematologic malignancies, including acute myeloid leukemia (AML).

Working in collaboration with MD Anderson, BSC will undertake this clinical Proof of Concept (PoC) trial of E6201, a dual-targeted FLT3 and MEK inhibitor for the high unmet need of FLT3 mutated AML. The trial is supported by recent translational data generated by Gautam Borthakur, MD, Michael Andreef, MD, PhD and colleagues in the Leukemia Department at MD Anderson. Dr. Borthakur will serve as Principal Investigator on the clinical trial.

Under this innovative agreement, MD Anderson commits its own resources to conduct the clinical study, while BSC provides the drug supply, study execution, safety monitoring, and data management. Both organizations will share the development challenges and risks for these high unmet need patients with advanced hematologic malignancies who need effective and new treatments.

This collaboration is a further step toward the realization of BSC’s “True” Open Innovation™ platform to develop drug candidates with potential to significantly improve patients’ health care. The BSC approach invites innovative clinical academic centers, such as MD Anderson, to participate more broadly in the clinical development process in an effort to share the risk and trial outcomes. The flexibility and collaborative approach of “True” Open Innovation™ empower centers like MD Anderson to become entrepreneurial partners together with BSC and the other members of its global network.

“We are very excited and pleased to work with MD Anderson, a leading cancer health care institution in which we share our core values of innovative patient-centered and science-based approaches,” says Keizo Koya, Ph.D., CEO of Boston Strategics. “This is a historical milestone for BSC to build on our concept of “True” Open Innovation™ by collaborating with such an institution as MD Anderson to create a new effective treatment for AML patients.”

“Our mission is to bring novel drugs to patients. Unfortunately there are drugs that, despite its promise, struggle to progress through clinical development. To bring those drugs to patients and unlock their full potential, we are firmly committed to working with the oncology community and to devise novel and creative business structures that make those collaborations possible“ says Ferran Prat, Ph.D., VP MD Anderson Cancer Center.

About Boston Strategics Corporation (BSC):

BSC is an integrated drug R&D company with experience in developing, managing and optimizing global drug development programs from late discovery, through translational research, first-in-man or proof-of-concept clinical studies. Its mission is to continuously improve patient health care by changing the drug R&D paradigm using “True” Open Innovation™ platform.

About “True” Open Innovation™ :

“True” Open Innovation™ is a revolutionary business concept that breaks through internal infrastructure limitations by drawing on the Boston Strategics core team of experts and introducing additional external, key expertise in a given area. In a highly specialized industry such as drug development, the limitation of large, internal organizations and the expertise of the internal team members is critical. “True” Open Innovation overcomes such limitations by reducing the need for large infrastructure, and draws on additional critical drug development expertise, based on the unique needs of a particular program. In summary Boston Strategics utilizes its own global core competencies coupled with external Strategic Global Outsourcing as needed.

Contact:
Strategia Therapeutics, Inc.
+1-781-761-0123 (office)
Contact@StrategiaTx.com (email)
http://www.StrategiaTx.com (website)

Key Agreement With Molecular Response

Posted on October 14, 2014June 11, 2015 by Editor

Boston Strategics Corporation Announces Key Agreement In Translational Oncology With Molecular Response

BOSTON, Oct. 14, 2014 /PRNewswire/ – Boston Strategics Corporation (BSC), an integrated clinical-stage drug research and development (R&D) company, Boston, MA, today announced that it has entered into an agreement with Molecular Response (MRL), a privately held molecular diagnostic services company and a leader in the identification of target populations for high value therapeutics. In collaboration with MRL, BSC designs and manages for pharmaceutical drug development programs to improve POS (Probability Of Success) identifying patient sub-populations using patient-derived tumor xenografts (PDX), leveraged by MRL’s proprietary ‘living’ cell bank of primary tumor cells.

This translational program and collaboration is another example of a BSCcollaboration, whereby BSC optimizes and executes the global strategy of key pharmaceutical partners’ drug development programs. Utilizing BSC‘s internal oncology development expertise and its ability to leverage the “True” Open Innovation network to collaborate with the best resources around the world, BSC continues to deliver more efficient and superior outcomes to key partners in treatment of cancer patients worldwide.

“We are excited to work with Boston Strategics to further refine the efficacy package of novel therapeutics for pharmaceutical partners and help the precision of their programs with more targeted approach to patient selection. The collaboration with these partners is proof of our success and continued commitment to enable further evaluation of cancer therapeutics in better characterized models with use of our high content cell-based platforms and exclusive patient-derived xenografts,” said Cyrus K. Mirsaidi, Molecular Response CEO.

“The selection of Molecular Response as a member of Boston Strategics‘ ’True’ Open Innovation platform, and access to their vast bank of characterized near patient models strengthens the ability of our network partners to address translational challenges and assess efficacy of compounds earlier in the life cycle of their programs,” said Dr. Keizo Koya, Boston Strategics, CEO. ”This approach combined with access to a large and well annotated primary tumor bank will allow foundational work for biomarker development, target population selection, and new indication mining for novel therapeutics.”

About Molecular Response:
Molecular Response is a leader in the utilization of large, clinically relevant tumor banks and predictive patient-derived xenografts (PDX) that help advance high value therapeutics through intelligently designed, biomarker driven in vitro and in vivo models. Our goal is to reduce risk and cost of therapeutic drug development for our partners by use of fully characterized efficacy models to create a clinically predictive knowledge base while fully integrated into existing pharmaceutical development processes and programs; Our results allow for the most informed decisions with best chance of success to advance therapeutic programs.

For additional information please visit www.molecularresponse.com.

Contact:
Strategia Therapeutics, Inc.
+1-781-761-0123 (office)
Contact@StrategiaTx.com (email)
http://www.StrategiaTx.com (website)